日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Pain Reduction in Linzagolix-Treated Patients With Uterine Fibroids: A Secondary Mediation Analysis of the PRIMROSE 1 and 2 Phase 3 Trials

Linzagolix治疗子宫肌瘤患者的疼痛缓解：PRIMROSE 1和2期3期试验的二次中介分析

期刊:Bjog-An International Journal of Obstetrics and Gynaecology
影响因子:4.3
doi:10.1111/1471-0528.18190
Becker, Sven; Dolmans, Marie-Madeleine; Herrera, Francisco Carmona; Petraglia, Felice; Renner, Stefan P; Ionescu-Ittu, Raluca; St-Pierre, Julien; Boolell, Mitra; Bestel, Elke; Hori, Satoshi; Donnez, Jacques
发表日期：2025
文献求助 收藏

A review of the pharmacology, clinical outcomes, and real-world effectiveness, safety, and non-contraceptive effects of NOMAC/E2

对NOMAC/E2的药理学、临床结果、真实世界中的有效性、安全性以及非避孕作用进行综述

期刊:European Journal of Obstetrics and Gynecology and Reproductive Biology: X
影响因子:1.7
doi:10.1016/j.eurox.2024.100283
Fruzzetti, Franca; Machado, Rogerio Bonassi; Lete, Iñaki; Patel, Amisha; Boolell, Mitra
发表日期：2024
文献求助 收藏

Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3)

Linzagolix 治疗与安慰剂治疗子宫内膜异位症相关疼痛患者的疗效比较：一项前瞻性、随机、双盲 3 期研究 (EDELWEISS 3)

期刊:Human Reproduction
影响因子:
doi:10.1093/humrep/deae076
Donnez, Jacques; Becker, Christian; Taylor, Hugh; Carmona Herrera, Francisco; Donnez, Olivier; Horne, Andrew; Paszkowski, Maciej; Petraglia, Felice; Renner, Stefan P; Patel, Amisha; Boolell, Mitra; Bestel, Elke; Dolmans, Marie-Madeleine
发表日期：2024
文献求助 收藏

Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain

在西班牙，每周服用35毫克肠溶利塞膦酸钠片与每周服用70毫克阿仑膦酸钠片治疗绝经后骨质疏松症的成本效益比较

期刊:Journal of Comparative Effectiveness Research
影响因子:2.5
doi:10.57264/cer-2023-0115
Casado, Enrique; Rosas, José; Rubio-Terrés, Carlos; Rubio-Rodríguez, Darío; Boolell, Mitra; Arístegui, Ignacio
代谢
骨质疏松
发表日期：2023
文献求助 收藏

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial

帕博利珠单抗联合同步放化疗治疗不可切除的局部晚期 III 期非小细胞肺癌患者：KEYNOTE-799 II 期非随机试验

期刊:Jama Oncology
影响因子:20.1
doi:10.1001/jamaoncol.2021.2301
Jabbour, Salma K; Lee, Ki Hyeong; Frost, Nikolaj; Breder, Valeriy; Kowalski, Dariusz M; Pollock, Theodore; Levchenko, Evgeny; Reguart, Noemi; Martinez-Marti, Alex; Houghton, Baerin; Paoli, Jean-Baptiste; Safina, Sufia; Park, Keunchil; Komiya, Takefumi; Sanford, Amy; Boolell, Vishal; Liu, Hong; Samkari, Ayman; Keller, Steven M; Reck, Martin
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2021
文献求助 收藏

The Evolution of Therapies in Non-Small Cell Lung Cancer

非小细胞肺癌治疗的发展历程

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers7030864
Boolell, Vishal; Alamgeer, Muhammad; Watkins, David N; Ganju, Vinod
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2015
文献求助 收藏